DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF VERSUS EPIRUBICIN, CMF AND WEEKLY DOCETAXEL OR PACLITAXEL FOLLOWED BY TRASTUZUMAB FOR ONE YEAR IN PATIENTS WITH EARLY BREAST CANCER

被引：0
|
作者：
Fountzilas, G. [1 ]
Gogas, H. [1 ]
Pavlidis, N. [1 ]
Eleftheraki, A. [1 ]
Skarlos, D. [1 ]
Koutras, A. [1 ]
Timotheadou, E. [1 ]
Papandreou, C. [1 ]
Pectasides, D. [1 ]
Dimopoulos, M. [1 ]
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Data Off, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [21] PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis
    Untch, M.
    von Minckwitz, G.
    Konecny, G. E.
    Conrad, U.
    Fett, W.
    Kurzeder, C.
    Lueck, H. -J.
    Stickeler, E.
    Urbaczyk, H.
    Liedtke, B.
    Beckmann, M. W.
    Salat, C.
    Harbeck, N.
    Mueller, V.
    Schmidt, M.
    Hasmueller, S.
    Lenhard, M.
    Nekljudova, V.
    Lebeau, A.
    Loibl, S.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 1999 - 2006
  • [22] Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophoshamid followed by docetaxel in primary breast cancer
    Cramer, EM
    Moers, C
    Zarghooni, V
    Bosse, K
    Mallmann, P
    Warm, M
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S231 - S231
  • [23] Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer
    Matsumoto, Akiko
    Jinno, Hiromitsu
    Naruse, Saki
    Isono, Yuka
    Maeda, Yuka
    Sato, Ayana
    Yamada, Miki
    Ikeda, Tatsuhiko
    Sasajima, Yuko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (12) : 1119 - 1124
  • [24] Epirubicin, paclitaxel and CMF as adjuvant treatment in node positive patients with operable breast cancer. Safety analysis of a randomized phase III study comparing two dose-dense sequential regimens.
    Fountzilas, G
    Gogas, H
    Papadimitriou, CH
    Kalofonos, HP
    Tsavdaridis, D
    Christodoulou, CH
    Briasoulis, E
    Bafaloukos, D
    Karina, M
    Markopoulos, CH
    Pectasides, D
    Karapanagiotis, K
    Papakostas, P
    Aravantinos, G
    Kosmidis, P
    Stathopoulos, GP
    Dimopoulos, AM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S108 - S108
  • [25] Preoperative dose-dense sequential chemotherapy of epirubicin/ cyclophosphamide followed by docetaxellcapecitabine in patients with early breast cancer: preliminary results
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 158 - 158
  • [26] Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+operable breast cancer
    Blakely, L.
    Somer, B.
    Keaton, M.
    Hermann, R.
    Schnell, F.
    Cobb, P.
    Johns, A.
    Walker, M.
    Schwartzberg, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] NEAT-A: Accelerated sequential epirubicin followed by higher dose 14 day CMF, using pegfilgrastim, is a feasible alternative for delivering dose dense E-CMF chemotherapy in early breast cancer
    Bowden, S.
    Gross, L.
    Poole, C. J.
    Hiller, L.
    Agrawal, R. K.
    McAdam, K. F.
    Earl, H. M.
    Anwar, S.
    Rea, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 194 - 195
  • [28] PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery
    Untch, M.
    Fasching, P. A.
    Bauerfeind, I.
    Conrad, U.
    Camara, O.
    Fett, W.
    Kuzeder, W.
    Lueck, H.
    Loibl, S.
    Von Minckwitz, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [30] Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophosphamide followed by docetaxel in primary breast cancer.
    Cramer, EM
    Moers, C
    Zarghooni, V
    Mallmann, P
    Warm, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 82S - 82S
12345